Cargando…

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19

BACKGROUND: The clinical outcomes of patients who decline anti-spike monoclonal antibody therapies for coronavirus disease-2019 (COVID-19) is not known. Factors associated with the decision to accept or decline the offer for anti-spike monoclonal antibody therapies are not established. This study ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bierle, Dennis M., Ganesh, Ravindra, Wilker, Caroline G., Hanson, Sara N., Moehnke, Darcie E., Jackson, Tammy A., Ramar, Priya, Rosedahl, Jordan K., Philpot, Lindsey M., Razonable, Raymund R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155772/ https://www.ncbi.nlm.nih.gov/pubmed/34032171 http://dx.doi.org/10.1177/21501327211019282

Ejemplares similares

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
por: Thilagar, Bright P., et al.
Publicado: (2022)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Central Sensitization Symptom Severity and Patient-Provider Relationships in a Community Setting
por: Wang, Xiao Jing, et al.
Publicado: (2021)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Managing Patients in the COVID-19 Pandemic: A Virtual Multidisciplinary Approach
por: Ganesh, Ravindra, et al.
Publicado: (2020)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Changes in substance use among young adults during a respiratory disease pandemic
por: Sharma, Pravesh, et al.
Publicado: (2020)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Dhand, Abhay, et al.
Publicado: (2022)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Loneliness and Migraine Self-Management: A Cross-Sectional Assessment
por: Lui, Jacob Z., et al.
Publicado: (2020)

Utilizing Administrative Data to Focus Quality Improvement Efforts for Opioid Prescribing in an Integrated Health System
por: Ramar, Priya, et al.
Publicado: (2018)

Depression and Anxiety Among Patients on Chronic Opioid Therapy
por: Elrashidi, Muhamad Y., et al.
Publicado: (2018)

Helpfulness of Clinical Visit Summary Content From Multi-Specialty Care: A Mixed-Methods Assessment
por: Ramar, Priya, et al.
Publicado: (2020)

Controlled Substance Agreements for Opioids in a Primary Care Practice
por: Philpot, Lindsey M., et al.
Publicado: (2017)

Changes in social relationships during an initial “stay-at-home” phase of the COVID-19 pandemic: A longitudinal survey study in the U.S.
por: Philpot, Lindsey M., et al.
Publicado: (2021)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Ensuring that informed consent is really an informed consent: Role of videography
por: Ghooi, Ravindra B.
Publicado: (2014)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

Association of a Remotely Offered Infectious Diseases eConsult Service With Improved Clinical Outcomes
por: Tande, Aaron J, et al.
Publicado: (2020)

778. ID Rocks It: Infectious Disease Remotely Offered Consultative Knowledge and Support via Inpatient Telehealth
por: Tande, Aaron J, et al.
Publicado: (2019)

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
por: Arimura, Ken, et al.
Publicado: (2023)

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Emergency Department-based monoclonal antibody therapy for patients with mild to moderate COVID-19
por: Devlin, Amanda, et al.
Publicado: (2023)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Cytomegalovirus Infections in Solid Organ Transplantation: A Review
por: Ramanan, Poornima, et al.
Publicado: (2013)

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

31 Emergency Department-Based Monoclonal Antibody Therapy for Patients With Mild to Moderate COVID-19
por: Lim, C., et al.
Publicado: (2021)

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus
por: Melendez, Dante P, et al.
Publicado: (2015)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

1536. Donor-Derived Mycobacterium tuberculosis Infection After Solid-Organ Transplantation: A Comprehensive Review
por: Abad, Cybele Lara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8gkf8mpt8rm0hjqp6mp9ao29ph